3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
3
NIH
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
35
Recurrence
27
Multiple Myeloma
27
Leukemia, Lymphocytic, Chronic, B-Cell
27
Lymphoma, Non-Hodgkin
25
Lymphoma
20
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, B-Cell
15
Lymphoma, Follicular
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Mantle-Cell
13
Leukemia
13
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
11
Ovarian Neoplasms
9
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Myelodysplastic Syndromes
6
Melanoma
6
Lymphoma, B-Cell, Marginal Zone
6
Breast Neoplasms
6
Liposarcoma, Myxoid
5
Colorectal Neoplasms
5
Burkitt Lymphoma
5
Interventions
Sorafenib
22
Bevacizumab
15
pembrolizumab
10
durvalumab
7
Nivolumab
7
Ipilimumab
6
Drug Therapy
6
atezolizumab
5
Talaporfin
5
spartalizumab
4
regorafenib
4
lenvatinib
4
derazantinib
3
Ramucirumab
3
Photochemotherapy
3
Leucovorin
3
Injections
3
Fluorouracil
3
Doxorubicin
3
tremelimumab
2
toripalimab
2
seocalcitol
2
relatlimab
2
phosphomannopentaose sulfate
2
liposomal doxorubicin
2
exatecan
2
cabozantinib
2
brivanib
2
Phototherapy
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liver Neoplasms
×
fludarabine
×
Clear all
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled